Search Results - "MENSSEN, Hans D"

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia by Hochhaus, Andreas, Larson, Richard A, Guilhot, François, Radich, Jerald P, Branford, Susan, Hughes, Timothy P, Baccarani, Michele, Deininger, Michael W, Cervantes, Francisco, Fujihara, Satoko, Ortmann, Christine-Elke, Menssen, Hans D, Kantarjian, Hagop, O’Brien, Stephen G, Druker, Brian J

“…After nearly 11 years of follow-up, long-term administration of imatinib was shown to be associated with prolonged control of chronic myeloid leukemia and no…”
Get full text

Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model by Menssen, Hans D., Harnack, Ulf, Erben, Ulrike, Neri, Dario, Hirsch, Burkhard, Dürkop, Horst

“…Purpose To analyze the impact of TNFα or IL2 on human lymphocytes in vitro and the anti-tumor and immune-modifying effects of L19-IL2 and L19-TNFα on…”
Get full text

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily by Hughes, Timothy P, Hochhaus, Andreas, Kantarjian, Hagop M, Cervantes, Francisco, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D, Rosti, Gianantonio, Ossenkoppele, Gert, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D, Kemp, Charisse, Larson, Richard A, Saglio, Giuseppe

“…In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in…”
Get full text

ED-B fibronectin as a target for antibody-based cancer treatments by Menrad, Andreas, Menssen, Hans D

“…Chemotherapeutic agents for the treatment of solid cancers do not discriminate between malignant and normal tissue, but rather depend on the increased…”
Get more information

Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants by Sechaud, Romain, Gu, Helen, Rahmanzadeh, Gholamreza, Chiparus, Ovidiu, Breitschaft, Astrid, Menssen, Hans D

“…PurposeMidostaurin, approved for FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis, is mainly metabolized by cytochrome P450 (CYP) 3A4…”
Get full text

Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants: Brief title: Drug-drug interaction of midostaurin by Sechaud, Romain, Gu, Helen, Rahmanzadeh, Gholamreza, Chiparus, Ovidiu, Breitschaft, Astrid, Menssen, Hans D.

“…Purpose Midostaurin, approved for FLT3 -mutated acute myeloid leukemia and advanced systemic mastocytosis, is mainly metabolized by cytochrome P450 (CYP) 3A4…”
Get full text

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib by Hughes, Timothy P., Saglio, Giuseppe, Kantarjian, Hagop M., Guilhot, François, Niederwieser, Dietger, Rosti, Gianantonio, Nakaseko, Chiaki, De Souza, Carmino Antonio, Kalaycio, Matt E., Meier, Stephan, Fan, Xiaolin, Menssen, Hans D., Larson, Richard A., Hochhaus, Andreas

“…We explored the impact of early molecular response (EMR; BCR-ABL ≤10% on the international scale [BCR-ABLIS] at 3 or 6 months) on outcomes in patients with…”
Get full text

Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma by MENSSEN, Hans D, SAKALOVA, Adriana, FIERE, Denis, HRUBISKO, Mikulas, THIEL, Eckhard, DELMAS, Pierre D, FONTANA, Aurélie, HERRMANN, Zuzana, BOEWER, Christian, FACON, Thierry, LICHINITSER, Michail R, SINGER, C. R. J, EULLER-ZIEGLER, Liana, WETTERWALD, Marc

“…Bisphosphonates have been found to reduce the incidence of skeletal-related events (SREs) in patients with multiple myeloma. This is the first double-blind,…”
Get full text

Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants by Sechaud, Romain, Gu, Helen, Rahmanzadeh, Gholamreza, Taylor, Amanda, Chiparus, Ovidiu, Sharma, Gopal Krishna, Breitschaft, Astrid, Menssen, Hans D.

“…Purpose Midostaurin, approved for treating FLT-3 -mutated acute myeloid leukemia and advanced systemic mastocytosis, is metabolized by cytochrome P450 (CYP)…”
Get full text

Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants by Sechaud, Romain, Gu, Helen, Rahmanzadeh, Gholamreza, Taylor, Amanda, Chiparus, Ovidiu, Sharma, Gopal Krishna, Breitschaft, Astrid, Menssen, Hans D.

Get full text

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis by Hartmann, Karin, Gotlib, Jason, Akin, Cem, Hermine, Olivier, Awan, Farrukh T., Hexner, Elizabeth, Mauro, Michael J., Menssen, Hans D., Redhu, Suman, Knoll, Stefanie, Sotlar, Karl, George, Tracy I., Horny, Hans-Peter, Valent, Peter, Reiter, Andreas, Kluin-Nelemans, Hanneke C.

“…Advanced systemic mastocytosis (advSM) is characterized by presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in…”
Get full text

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina by Wang, Jianxiang, Shen, Zhi-Xiang, Saglio, Giuseppe, Jin, Jie, Huang, He, Hu, Yu, Du, Xin, Li, Jianyong, Meng, Fanyi, Zhu, Huanling, Hu, Jianda, Wang, Jianmin, Hou, Ming, Hertle, Sabine, Menssen, Hans D., Ortmann, Christine-Elke, Tribouley, Catherine, Yuan, Ye, Baccarani, Michele, Huang, Xiaojun

“…Treatment with a tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 is currently the standard of care for patients with chronic myeloid leukemia (CML) in…”
Get full text

Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation by Ho, Jenny N.H.G., Schmidt, Dominik, Lowinus, Theresa, Ryoo, Jeongmin, Dopfer, Elaine-Pashupati, Gonzalo Núñez, Nicolás, Costa-Pereira, Sara, Toffalori, Cristina, Punta, Marco, Fetsch, Viktor, Wertheimer, Tobias, Rittmann, Marie-Claire, Braun, Lukas M., Follo, Marie, Briere, Christelle, Vinnakota, Janaki Manoja, Langenbach, Marlene, Koppers, Felicitas, Shoumariyeh, Khalid, Engel, Helena, Rückert, Tamina, Märklin, Melanie, Holzmayer, Samuel, Illert, Anna L., Magon, Federica, Andrieux, Geoffroy, Duquesne, Sandra, Pfeifer, Dietmar, Staniek, Julian, Rizzi, Marta, Miething, Cornelius, Köhler, Natalie, Duyster, Justus, Menssen, Hans D., Boerries, Melanie, Buescher, Joerg M., Cabezas-Wallscheid, Nina, Blazar, Bruce R., Apostolova, Petya, Vago, Luca, Pearce, Erika L., Becher, Burkhard, Zeiser, Robert

“…Patients with acute myeloid leukemia (AML) often achieve remission after allogeneic hematopoietic cell transplantation (allo-HCT) but subsequently die of…”
Get full text

MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production by Langenbach, Marlene, Giesler, Sophie, Richtsfeld, Stefan, Costa-Pereira, Sara, Rindlisbacher, Lukas, Wertheimer, Tobias, Braun, Lukas M, Andrieux, Geoffroy, Duquesne, Sandra, Pfeifer, Dietmar, Woessner, Nadine M, Menssen, Hans D, Taromi, Sanaz, Duyster, Justus, Börries, Melanie, Brummer, Tilman, Blazar, Bruce R, Minguet, Susana, Turko, Patrick, Levesque, Mitchell P, Becher, Burkhard, Zeiser, Robert

“…The treatment of patients with metastatic melanoma with immune checkpoint inhibitors (ICI) leads to impressive response rates but primary and secondary…”
Get full text

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma by EIGENTLER, Thomas K, WEIDE, Benjamin, LOVATO, Valeria, KASPAR, Manuela, TRACHSEL, Eveline, MENSSEN, Hans D, NERI, Dario, GARBE, Claus, DE BRAUD, Filippo, SPITALERI, Gianluca, ROMANINI, Antonella, PFLUGFELDER, Annette, GONZALEZ-LGLESIAS, Reinerio, TASCIOTTI, Annaelisa, GIOVANNONI, Leonardo, SCHWAGER, Kathrin

“…L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of fibronectin, a tumor angiogenesis marker, and of human…”
Get full text

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma by Johannsen, Manfred, Spitaleri, Gianluca, Curigliano, Giuseppe, Roigas, Jan, Weikert, Steffen, Kempkensteffen, Carsten, Roemer, Andreas, Kloeters, Christian, Rogalla, Patrik, Pecher, Gabriele, Miller, Kurt, Berndt, Alexander, Kosmehl, Hartwig, Trachsel, Eveline, Kaspar, Manuela, Lovato, Valeria, González-Iglesias, Reinerio, Giovannoni, Leonardo, Menssen, Hans D, Neri, Dario, de Braud, Filippo

“…Abstract Background L19-IL2, a tumour-targeting immunocytokine composed of the recombinant human antibody fragment L19 (specific to the alternatively-spliced…”
Get full text

Aggressive Lymphoma after CD19 CAR T-Cell Therapy by Kobbe, Guido, Brüggemann, Monika, Baermann, Ben-Niklas, Wiegand, Laura, Trautmann, Heiko, Yousefian, Schayan, Libertini, Silvana, Menssen, Hans D., Maier, Harald J., Ulrich, Peter, Gao, Jingbo, Bruch, Peter-Martin, Liebers, Nora, Radujkovic, Aleksandar, Seifert, Marc, Schniederjohann, Christina, Paramasivam, Nagarajan, Fitzgerald, Donnacha, Seidel, Maximilian, Esposito, Irene, Germing, Ulrich, Cadeddu, Ron-Patrick, Nachtkamp, Kathrin, Jäger, Paul, Ulrych, Thomas, Fischer, Johannes C., Rox, Jutta M., Giesel, Frederik, Koch, Raphael, Antoch, Gerald, Distler, Jörg H.W., Meuth, Sven G., Jacobsen, Malte, Hübschmann, Daniel, Lu, Junyan, Iaccarino, Ingram, Haas, Simon, Damm, Frederik, Dietrich, Sascha

“…The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month…”
Get full text

Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice by Talvard-Balland, Nana, Braun, Lukas M, Dixon, Karen O, Zwick, Melissa, Engel, Helena, Hartmann, Alina, Duquesne, Sandra, Penter, Livius, Andrieux, Geoffroy, Rindlisbacher, Lukas, Acerbis, Andrea, Ehmann, Jule, Köllerer, Christoph, Ansuinelli, Michela, Rettig, Andres, Moschallski, Kevin, Apostolova, Petya, Brummer, Tilman, Illert, Anna L, Schramm, Markus A, Cheng, Yurong, Köttgen, Anna, Duyster, Justus, Menssen, Hans D, Ritz, Jerome, Blazar, Bruce R, Boerries, Melanie, Schmitt-Gräff, Annette, Sariipek, Nurefsan, Van Galen, Peter, Buescher, Joerg M, Cabezas-Wallscheid, Nina, Pahl, Heike L, Pearce, Erika L, Soiffer, Robert J, Wu, Catherine J, Vago, Luca, Becher, Burkhard, Köhler, Natalie, Wertheimer, Tobias, Kuchroo, Vijay K, Zeiser, Robert

“…Leukemia relapse is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). We tested the potential of targeting T cell (Tc)…”
Get full text

Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells by Dietrich, Thore, Hucko, Thomas, Schneemann, Christiane, Neumann, Marleen, Menrad, Andreas, Willuda, Joerg, Atrott, Kirstin, Stibenz, Dietger, Fleck, Eckart, Graf, Kristof, Menssen, Hans D

“…Abstract Objective Recent studies indicate that regulatory T cells (Tregs) attenuate murine atherosclerosis. Since interleukin (IL)-2 induces Tregs…”
Get full text

Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies by Erba, Paola A, Sollini, Martina, Orciuolo, Enrico, Traino, Claudio, Petrini, Mario, Paganelli, Giovanni, Bombardieri, Emilio, Grana, Chiara, Giovannoni, Leonardo, Neri, Dario, Menssen, Hans D, Mariani, Giuliano

“…We present here a systematic analysis of lymphoma and MM patients recruited into 2 clinical trials or treated with radretumab according to compassionate use,…”
Get full text